• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Belatacept reduces skin cancer risk in kidney transplant recipients.

作者信息

Wang Mike, Mittal Amit, Colegio Oscar R

机构信息

Department of Dermatology, Yale New Haven Hospital, Yale School of Medicine, New Haven, Connecticut.

Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts.

出版信息

J Am Acad Dermatol. 2020 Apr;82(4):996-998. doi: 10.1016/j.jaad.2019.09.070. Epub 2019 Oct 4.

DOI:10.1016/j.jaad.2019.09.070
PMID:31589945
Abstract
摘要

相似文献

1
Belatacept reduces skin cancer risk in kidney transplant recipients.贝拉西普可降低肾移植受者患皮肤癌的风险。
J Am Acad Dermatol. 2020 Apr;82(4):996-998. doi: 10.1016/j.jaad.2019.09.070. Epub 2019 Oct 4.
2
Declining incidence of keratinocyte carcinoma in organ transplant recipients.器官移植受者中角质形成细胞癌发病率的下降
Br J Dermatol. 2019 Nov;181(5):983-991. doi: 10.1111/bjd.18094.
3
Safety and Efficacy Outcomes 3 Years After Switching to Belatacept From a Calcineurin Inhibitor in Kidney Transplant Recipients: Results From a Phase 2 Randomized Trial.在肾移植受者中从钙调磷酸酶抑制剂转换至贝利尤单抗后的 3 年安全性和疗效结局：一项 2 期随机试验的结果。
Am J Kidney Dis. 2017 May;69(5):587-594. doi: 10.1053/j.ajkd.2016.09.021. Epub 2016 Nov 23.
4
Skin cancer in kidney transplant recipients affected with autosomal dominant polycystic kidney disease.患有常染色体显性多囊肾病的肾移植受者的皮肤癌
Clin Transplant. 2016 Apr;30(4):339-43. doi: 10.1111/ctr.12707. Epub 2016 Feb 24.
5
Chemoprevention of keratinocyte carcinoma and actinic keratosis in solid-organ transplant recipients: Systematic review and meta-analyses.实体器官移植受者中角质形成细胞癌和光化性角化病的化学预防：系统评价和荟萃分析。
J Am Acad Dermatol. 2021 Feb;84(2):528-530. doi: 10.1016/j.jaad.2020.04.160. Epub 2020 May 5.
6
Non-melanoma skin cancer in Portuguese kidney transplant recipients - incidence and risk factors.葡萄牙肾移植受者的非黑色素瘤皮肤癌——发病率及危险因素
An Bras Dermatol. 2016 Jul-Aug;91(4):455-62. doi: 10.1590/abd1806-4841.20164891.
7
Belatacept prophylaxis against organ rejection in adult kidney-transplant recipients.贝拉西普预防成人肾移植受者器官排斥反应。
Expert Rev Clin Pharmacol. 2016;9(2):215-27. doi: 10.1586/17512433.2016.1112736. Epub 2015 Dec 22.
8
Switching renal transplant recipients to belatacept therapy: results of a real-life gradual conversion protocol.将肾移植受者转换为贝利尤单抗治疗：真实生活中逐步转换方案的结果。
Transpl Immunol. 2019 Oct;56:101207. doi: 10.1016/j.trim.2019.04.002. Epub 2019 May 6.
9
Temporal trends and current use of de novo belatacept in kidney transplant recipients in the United States.美国肾移植受者中新型贝拉西普的时间趋势及当前使用情况。
Clin Transplant. 2022 Mar;36(3):e14531. doi: 10.1111/ctr.14531. Epub 2021 Nov 29.
10
Belatacept rescue conversion in kidney transplant recipients with vascular lesions (Banff cv score >2):  a retrospective cohort study.贝那普利塞抢救治疗伴血管病变（Banff cv 评分>2）的肾移植受者：一项回顾性队列研究。
Nephrol Dial Transplant. 2023 Feb 13;38(2):481-490. doi: 10.1093/ndt/gfac178.

引用本文的文献

1
Belatacept and non-melanoma skin cancer risk in kidney transplant recipients: a narrative review from a mechanistic and clinical perspective.贝拉西普与肾移植受者非黑色素瘤皮肤癌风险：基于机制和临床视角的叙述性综述
BMC Nephrol. 2025 Aug 23;26(1):487. doi: 10.1186/s12882-025-04373-z.
2
Immunosuppressants/Immunomodulators and Malignancy.免疫抑制剂/免疫调节剂与恶性肿瘤
J Clin Med. 2025 Jul 21;14(14):5160. doi: 10.3390/jcm14145160.
3
Real-world evidence regarding cancer, mortality, and graft failure risk with de novo belatacept use among kidney transplant recipients in the United States.
关于美国肾移植受者中初治使用贝拉西普的癌症、死亡率和移植失败风险的真实世界证据。
Am J Transplant. 2025 Aug;25(8):1723-1734. doi: 10.1016/j.ajt.2025.03.004. Epub 2025 Mar 8.
4
Clinical Implications of Skin Cancer in Kidney Transplant Recipients in the Era of Immune Checkpoint Inhibitors.免疫检查点抑制剂时代肾移植受者皮肤癌的临床意义
J Clin Med Res. 2024 Dec;16(12):571-577. doi: 10.14740/jocmr6088. Epub 2024 Dec 20.
5
Cancer Screening and Cancer Treatment in Kidney Transplant Recipients.肾移植受者的癌症筛查和癌症治疗。
Kidney360. 2024 Oct 1;5(10):1569-1583. doi: 10.34067/KID.0000000000000545.
6
Cutaneous Squamous Cell Carcinoma in Patients with Solid-Organ-Transplant-Associated Immunosuppression.实体器官移植相关免疫抑制患者的皮肤鳞状细胞癌
Cancers (Basel). 2024 Sep 4;16(17):3083. doi: 10.3390/cancers16173083.
7
De novo belatacept does not reduce the rate of skin cancer in renal transplant recipients compared to standard therapy.与标准疗法相比，肾移植受者使用从头开始的贝拉西普并不能降低皮肤癌的发生率。
J Am Acad Dermatol. 2024 Oct;91(4):720-722. doi: 10.1016/j.jaad.2024.05.068. Epub 2024 Jun 4.
8
Updates in Skin Cancer in Transplant Recipients and Immunosuppressed Patients: Review of the 2022-2023 Scientific Symposium of the International Immunosuppression and Transplant Skin Cancer Collaborative.移植受者和免疫抑制患者皮肤癌的最新进展：2022-2023 年国际免疫抑制与移植皮肤癌协作组科学研讨会综述。
Transpl Int. 2024 Mar 18;37:12387. doi: 10.3389/ti.2024.12387. eCollection 2024.
9
Interventions After First Post-Transplant Cutaneous Squamous Cell Carcinoma: A Proposed Decision Framework.首次移植后皮肤鳞状细胞癌后的干预措施：一个建议的决策框架。
Transpl Int. 2022 Nov 22;35:10880. doi: 10.3389/ti.2022.10880. eCollection 2022.